All Pharma News
EyePoint Reports Inducement Grants Under Nasdaq Rule 5635(c)(4)

EyePoint Reports Inducement Grants Under Nasdaq Rule 5635(c)(4)
GLOBENEWSWIRE
16 Jul 2024
Share Share
EyePoint Pharmaceuticals to Highlight DURAVYU (Vorolanib) Clinical Progress

EyePoint Pharmaceuticals to Highlight DURAVYU (Vorolanib) Clinical Progress
GLOBENEWSWIRE
26 Jun 2024
Share Share
EyePoint To Host R&D Day On June 26, 2024

EyePoint To Host R&D Day On June 26, 2024
GLOBENEWSWIRE
18 Jun 2024
Share Share
EyePoint Pharmaceuticals Reports Inducement Grants Under Nasdaq Rule 5635(c)(4)

EyePoint Pharmaceuticals Reports Inducement Grants Under Nasdaq Rule 5635(c)(4)
GLOBENEWSWIRE
17 Jun 2024
Share Share
EyePoint Pharma: Presenting At Goldman Sachs Healthcare Conference

EyePoint Pharma: Presenting At Goldman Sachs Healthcare Conference
GLOBENEWSWIRE
05 Jun 2024
Share Share
EyePoint Reports Inducement Grants Under Nasdaq 5635(c)(4)

EyePoint Reports Inducement Grants Under Nasdaq 5635(c)(4)
GLOBENEWSWIRE
16 May 2024
Share Share
EyePoint Pharma Q1 2024 Results, Corporate Updates

EyePoint Pharma Q1 2024 Results, Corporate Updates
GLOBENEWSWIRE
08 May 2024
Share Share
EyePoint reports Duravyu trial fail, raising questions

EyePoint reports Duravyu trial fail, raising questions
Eric Sagonowsky FIERCE PHARMA
06 May 2024
Share Share
EyePoint`s DURAVYU™ Topline Phase 2 Diabetic Retinopathy Data

EyePoint`s DURAVYU™ Topline Phase 2 Diabetic Retinopathy Data
GLOBENEWSWIRE
06 May 2024
Share Share
Mirae Asset Global Investments Co. Ltd. Purchases 882 Shares of EyePoint

Mirae Asset Global Investments Co. Ltd. Purchases 882 Shares of EyePoint
DEFENSWORLD
27 Apr 2024
Share Share